Mentor Capital, Inc. Site Map

Alphabetical Sitemap

• Mentor Capital (MNTR) Invests in Cancer Immunotherapy Index Companies
• Changing Assets & Acquisitions
• Warrant Information
• Chairman's Letters

• Bringing It All Together To Win In The Cancer Fight (2011)
• Welcome To The Team Leading The Cancer Fight (2010)

• Medicine, Science & The Economy

• Sunlight Explains Japan Radiation Risk

• Press Releases

• Mentor Capital Acquires 50 Percent of Brighter Day Health For $5M
• Mentor Capital Begins its 2012 Cancer Roll-up Strategy
• MNTR acquires 30 Percent of European Cancer Vaccine for $4.71 Million
• Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine
• Mentor Capital Reports Mid-Year Profits for 2011
• Mentor Capital Initiates Discussions for Potential Merger
• Mentor Capital Seeks Funding Partners as Neutron Cancer Therapy Accelerates
• Cancer Immunotherapy Index Outpaces Biotechs
• Increased Chinese and International Visitors to Mentor Capital Site
• CEO Purchases an Additional 3.14 Percent of MNTR Shares
• MNTR Drafts Five Cancer Funding Contracts for $40 Million
• MNTR Screens Cancer Companies For Investment At ASCO
• MNTR Acquires $5M Hadron Neutron Therapy Interest
• $125 Million for Socially Responsible Direct Cancer Funding
• Advaxis Added To Cancer Immunotherapy Index
• MNTR In Discussion With Breast Cancer Immunotherapy Company
• Nobel Laureate Reinforces the Mentor Capital Strategy to Fund
• Mentor Capital to Expand Funding Bridge Over Cancer Development Gap
• Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval of $93,000 Provenge Immunotherapy Treatment by Dendreon for Prostate Cancer
• Mentor Capital Sees a Shift to Public Acceptance of Dendreon-like
• Mentor Capital Cancer Immunotherapy Index Gains on Health Care Bill 12-Year Exclusive Period for Biologic Drugs
• Provectus Pharmaceuticals, Inc. Added to Cancer Immunotherapy Index by Mentor Capital, Inc. Experiences 23% One-Week Gain
• Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
• Mentor Capital Retains Network 1 Financial Securities for Comprehensive Investment Banking Services
• Mentor Capital Announces Plan for New 2010 Actively Managed Cancer Immunotherapy Index and 45 Day Call on C Warrants for CI Index Seed Funding
• Mentor Capital, Inc. Speaks on Cancer Investment with Long Island Investment Banking Group
• Quantum Immunologics Achieves Major Funding in Support of Ongoing FDA Trials
• Mentor Capital, Inc. Gains 135% and Calls in $3 Million Equity Tranche
• Mentor Capital, Inc. (MNTR) Initiates Trading at $1.05/sh (P/E of 2.7x)

• Survivors Say Thanks
• Cancer Resources
• Safe Harbor Statement
• Information For Brokers
• Shareholder Updates
• Frequently Asked Questions
• Contact Mentor Capital, Inc.

• Thank You for Contacting Mentor Capital

• About Mentor Capital

• About MNTR
• Summary Data
• Management Team
• Professional Support
• Philosophy
• Ethics
• Corporate Governance

• Investor's Corner (Contract)
• Analysts' Coverage

• $5/Share - Sr. Securities Analyst

• Cancer Imm Index Information
• Cancer Immunotherapy Index
• Visit Portfolio Companies
• Site Map